SG11202109194UA - Pyrazolopyridine compounds for ire1 inhibition - Google Patents
Pyrazolopyridine compounds for ire1 inhibitionInfo
- Publication number
- SG11202109194UA SG11202109194UA SG11202109194UA SG11202109194UA SG11202109194UA SG 11202109194U A SG11202109194U A SG 11202109194UA SG 11202109194U A SG11202109194U A SG 11202109194UA SG 11202109194U A SG11202109194U A SG 11202109194UA SG 11202109194U A SG11202109194U A SG 11202109194UA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolopyridine compounds
- ire1
- inhibition
- ire1 inhibition
- pyrazolopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811237P | 2019-02-27 | 2019-02-27 | |
| US201962813975P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/020162 WO2020176765A1 (fr) | 2019-02-27 | 2020-02-27 | Composés de pyrazolopyridine pour l'inhibition d'ire1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109194UA true SG11202109194UA (en) | 2021-09-29 |
Family
ID=72238956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109194UA SG11202109194UA (en) | 2019-02-27 | 2020-02-27 | Pyrazolopyridine compounds for ire1 inhibition |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220153734A1 (fr) |
| EP (1) | EP3930718A4 (fr) |
| JP (1) | JP2022521784A (fr) |
| KR (1) | KR20210139280A (fr) |
| CN (1) | CN113795254A (fr) |
| AU (1) | AU2020228644A1 (fr) |
| BR (1) | BR112021016974A2 (fr) |
| CA (1) | CA3131388A1 (fr) |
| IL (1) | IL285794A (fr) |
| MX (1) | MX2021010345A (fr) |
| SG (1) | SG11202109194UA (fr) |
| WO (1) | WO2020176765A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US8980899B2 (en) * | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| JP2015532287A (ja) * | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１の調節 |
| WO2016004254A1 (fr) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Modulation combinée d'ire1 |
| CA3016196A1 (fr) * | 2016-03-03 | 2017-09-08 | Cornell University | Inhibiteurs ire1-alpha a petites molecules |
| WO2018161033A1 (fr) * | 2017-03-02 | 2018-09-07 | Wright, Adrian | Inhibiteurs ire1-alpha à petites molécules |
| CA3064837A1 (fr) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Petites molecules inhibitrices d'ire1 |
| IL272845B2 (en) * | 2017-09-01 | 2023-12-01 | Optikira Llc | Compounds and preparations for inhibiting IRE1 |
-
2020
- 2020-02-27 WO PCT/US2020/020162 patent/WO2020176765A1/fr unknown
- 2020-02-27 JP JP2021549956A patent/JP2022521784A/ja active Pending
- 2020-02-27 US US17/432,842 patent/US20220153734A1/en active Pending
- 2020-02-27 CN CN202080031022.8A patent/CN113795254A/zh active Pending
- 2020-02-27 BR BR112021016974A patent/BR112021016974A2/pt unknown
- 2020-02-27 KR KR1020217030762A patent/KR20210139280A/ko unknown
- 2020-02-27 SG SG11202109194UA patent/SG11202109194UA/en unknown
- 2020-02-27 EP EP20762408.1A patent/EP3930718A4/fr active Pending
- 2020-02-27 CA CA3131388A patent/CA3131388A1/fr active Pending
- 2020-02-27 AU AU2020228644A patent/AU2020228644A1/en active Pending
- 2020-02-27 MX MX2021010345A patent/MX2021010345A/es unknown
-
2021
- 2021-08-23 IL IL285794A patent/IL285794A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930718A1 (fr) | 2022-01-05 |
| JP2022521784A (ja) | 2022-04-12 |
| IL285794A (en) | 2021-10-31 |
| CN113795254A (zh) | 2021-12-14 |
| US20220153734A1 (en) | 2022-05-19 |
| BR112021016974A2 (pt) | 2021-11-30 |
| CA3131388A1 (fr) | 2020-09-03 |
| KR20210139280A (ko) | 2021-11-22 |
| MX2021010345A (es) | 2021-12-15 |
| EP3930718A4 (fr) | 2022-10-05 |
| WO2020176765A1 (fr) | 2020-09-03 |
| AU2020228644A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277006A (en) | CD73 inhibitors | |
| GB201911928D0 (en) | Pharmaceutical compounds | |
| GB201905265D0 (en) | Inflammasome inhibition | |
| IL304348A (en) | cd73 inhibitors | |
| ZA202001320B (en) | Compounds and compositions for ire1 inhibition | |
| EP4051688A4 (fr) | Inhibiteurs de cd73 | |
| GB201819126D0 (en) | Inhibitor compounds | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| IL290087A (en) | inhibitory substances | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| IL288292A (en) | Oxathiazine compounds for gapdh inhibition | |
| IL291570A (en) | Pharmaceutical preparations | |
| EP3930712A4 (fr) | Composés d'imidazolopyrazine pour inhibition d'ire1 | |
| IL285794A (en) | Pyrazolopyridine compounds for ire1 inhibition | |
| GB201905328D0 (en) | Inhibitor compounds | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| EP3820847A4 (fr) | Composés améliorés pour l'inhibition de myc | |
| GB201809113D0 (en) | Compounds for new use | |
| GB201918657D0 (en) | Compounds for new use | |
| GB201919213D0 (en) | Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds | |
| PT3710446T (pt) | Compostos úteis para inibir cdk7 |